IoM’s Drug Safety Cmte. Will Meet In June; Panel Includes Ex-FDAer Ellenberg
Executive Summary
The Institute of Medicine's Drug Safety Committee will convene June 8 to begin discussing its review of FDA's post-marketing oversight system
You may also be interested in...
FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed
FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September
IoM Drug Safety Review Should Reach Beyond FDA, Agency’s Woodcock Says
The scope of the Institute of Medicine's assessment of the U.S. drug safety system must extend beyond an evaluation of FDA's capabilities, FDA Acting Deputy Commissioner for Operations Janet Woodcock said June 8
FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed
FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September